Cadre Holdings heads into its Q1 2026 earnings today with a notable insider overhang — CEO Warren Kanders sold $6.3 million of stock in mid-March, just weeks before the release.
The headline trades are hard to ignore. Kanders, who holds roughly 26% of the company, dumped 200,000 shares in two tranches on March 20 and March 23, pocketing an average of just over $31.60 per share. That came on the heels of a dramatic earnings miss in March — the company fell 21.5% on the day of its Q4 report and shed another 20.8% over the following five trading sessions. The CEO was selling near current prices almost immediately after that collapse. Net insider activity over the prior 90 days is technically positive at $7 million, but that figure is inflated by equity award grants; the actual open-market selling pattern tells a more cautious story.
Short interest corroborates the guarded tone. At 5.2% of the free float, SI is modest but has been grinding higher — up roughly 4.7% over the past month and 2.6% on the week. Days to cover is elevated at 12.5 days on the FINRA-reported figure, placing CDRE in the 4th percentile by DTC rank. Borrow costs remain low at under 0.5%, and availability is not tight, so there is no squeeze dynamic in play. The short score of 57 is middling — elevated enough to warrant attention but not flashing extreme bearish conviction.
Options positioning offers a contrasting signal. Call interest has been running ahead of puts, with the put/call ratio at 0.44 — well below its 20-day average of 0.51 and a full standard deviation below the mean. That leans bullish, though the PCR has drifted lower steadily over the past two weeks as the stock recovered 6.7% from its recent lows. The rebound has not been enough to erase a 27% year-to-date drawdown; at $31.36, the stock remains deep below the analyst consensus target of $48.80. That gap implies significant upside on paper, though analyst data has not been updated since mid-March and the most recent major action — a Bank of America downgrade to Underperform in August 2025 with a $26 target — is a reminder that the street is split.
The bull case rests on valuation: a P/E of 22x and EV/EBITDA of 10.4x for a defense and body-armor business with recurring government demand could look attractive if revenues recover. Bears point to the March quarter's sharp earnings miss, the CEO's decision to sell into the bounce, and EPS momentum scores that rank in the bottom quartile of the universe. The print today will test whether Q1 revenue trends — estimated near $155 million — show any stabilisation after the Q4 stumble, and whether management's outlook is enough to convince the market the worst is behind Cadre.
See the live data behind this article on ORTEX.
Open CDRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
